Summary:
- Ryght AI, a company based in Laguna Beach, CA, secured $3 million in seed funding for their real-time generative AI solutions in the clinical research industry.
- The funding round was led by Foothill Ventures and included participation from existing investors like AIX Ventures and Virtue Ventures.
- Ryght AI’s platform automates clinical trial site selection, activation, and enrollment processes, collaborating with over 100,000 trial sites to accelerate trials, reduce costs, and enhance patient access to new therapies.
Article:
Ryght AI Secures $3 Million in Seed Funding for Innovative AI Solutions in Clinical Research
Ryght AI, a cutting-edge company headquartered in Laguna Beach, CA, has recently announced the successful acquisition of $3 million in seed funding to further develop their real-time generative AI solutions tailored for the clinical research industry. The funding round was spearheaded by Foothill Ventures, with additional contributions from existing investors such as AIX Ventures, Virtue Ventures, IASO Ventures, Top Harvest Capital, and Page One Ventures.
Founded in 2024 by Simon Arkell, Ryght AI aims to revolutionize the clinical research landscape by offering an agentic-AI platform that streamlines and automates crucial processes like clinical trial site selection, activation, and patient enrollment. By leveraging generative-AI agents and a secure digital-twin network boasting over 100,000 trial sites, the company ensures SOC 2 compliance and provides integrated applications for sponsors, CROs, and research sites. This unique approach enables Ryght AI to deliver "service as software," expediting trials, cutting down costs, and improving patient access to innovative therapies.
One of the key features of Ryght AI’s platform is its ability to tap into a live global network of over 100,000 "digital twin" site profiles, allowing it to intelligently analyze complex trial protocols and connect them with the most suitable sites for success. This streamlined process accelerates contract completion and patient enrollment, ultimately facilitating rapid and timely access to clinical trials for eligible patients.
Moreover, Ryght AI has successfully established partnerships with prestigious academic medical centers, including Emory University, West Virginia University, West Clinic, and others. These collaborations complement the company’s existing partnerships with The University of Southern California Keck School of Medicine and the Medical College of Wisconsin, further solidifying Ryght AI’s position as a frontrunner in the clinical research industry.
In conclusion, Ryght AI’s recent funding success and strategic partnerships underscore the company’s commitment to driving innovation in clinical research through advanced AI solutions. With a focus on accelerating trials, reducing costs, and enhancing patient access to cutting-edge therapies, Ryght AI is poised to make a significant impact on the future of healthcare.
